Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
MeSH terms
-
Biomarkers / analysis
-
Drug Approval* / economics
-
Drug Approval* / legislation & jurisprudence
-
Health Policy*
-
Humans
-
Orphan Drug Production* / economics
-
Orphan Drug Production* / legislation & jurisprudence
-
Rare Diseases / drug therapy
-
United States
-
United States Food and Drug Administration